Alpha Cognition (NASDAQ:ACOG) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Alpha Cognition (NASDAQ:ACOG) from a hold rating to a sell rating in a research report released on Saturday morning.

A number of other analysts also recently weighed in on ACOG. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Alpha Cognition in a research report on Monday, April 27th. Craig Hallum started coverage on Alpha Cognition in a research report on Friday, April 17th. They set a “buy” rating and a $14.00 target price for the company. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $16.00.

Alpha Cognition Price Performance

Shares of NASDAQ ACOG opened at $5.95 on Friday. The stock’s fifty day moving average price is $6.06 and its two-hundred day moving average price is $5.98. Alpha Cognition has a one year low of $4.50 and a one year high of $11.54. The firm has a market cap of $129.53 million, a price-to-earnings ratio of -5.13 and a beta of 2.39.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Alpha Cognition had a negative net margin of 202.23% and a negative return on equity of 55.71%. The firm had revenue of $2.60 million during the quarter, compared to analyst estimates of $4.41 million. On average, equities analysts anticipate that Alpha Cognition will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of Alpha Cognition

A number of institutional investors have recently modified their holdings of the stock. Berkshire Asset Management LLC PA lifted its position in shares of Alpha Cognition by 50.7% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock valued at $116,000 after acquiring an additional 6,000 shares during the period. Villere ST Denis J & Co. LLC lifted its position in shares of Alpha Cognition by 13.2% during the 4th quarter. Villere ST Denis J & Co. LLC now owns 73,875 shares of the company’s stock valued at $480,000 after acquiring an additional 8,617 shares during the period. Green Alpha Advisors LLC bought a new stake in shares of Alpha Cognition during the 4th quarter valued at $72,000. Geode Capital Management LLC bought a new stake in shares of Alpha Cognition during the 2nd quarter worth $112,000. Finally, Massar Capital Management LP bought a new stake in shares of Alpha Cognition during the 2nd quarter worth $116,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.